Bleeding disorders are a group of conditions in which there is a problem with the body's blood clotting process. These disorders can lead to heavy and prolonged bleeding after an injury. Bleeding can also begin on its own.
Normal blood clotting involves as many as 20 different plasma proteins, which are known as blood clotting or coagulation factors. These factors act together with other chemicals to form a substance called fibrin that stops bleeding.
Treatments such as the use of drugs to stop blood clots (anticoagulants) or the long-term use of antibiotics
Bleeding disorders can also result from having poorly working or too few of the blood cells that promote blood clotting (platelets). These disorders can also be either inherited or picked up (acquired). The side effects of certain drugs often lead to the acquired forms.
Treatment depends on the type of disorder. It may include:
Factor replacement
Fresh frozen plasma transfusion
Platelet transfusion
Other therapies
Expectations (prognosis)
The outcome also depends on the disorder. Most primary bleeding disorders can be managed. Those due to diseases, such as DIC, depend on how well the disease that is causing the bleeding disorder is treated.
Complications
Bleeding in the brain
Severe bleeding (usually from the gastrointestinal tract or injuries)
Other complications can occur, depending on the disorder.
Calling your health care provider
Call your health care provider if you notice any unusual or severe bleeding.
Prevention
Prevention depends on the specific disorder.
References
Coller BS, Schneiderman PI. Clinical evaluation of hemorrhagic disorders: the bleeding history and differential diagnosis of purpura. In: Hoffman R, Benz EJ Jr., Shattil SJ, et al, eds. Hoffman Hematology: Basic Principles and Practice. 5th ed. Philadelphia, Pa: Churchill Livingstone Elsevier; 2008:chap 121.
Review Date:
2/28/2011
Reviewed By:
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.